Point72 Asset Management
CGON icon

Point72 Asset Management’s CG Oncology CGON Stock Holding History

Point72 Asset Management’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.75M Buy
+25,900
New +$1.47M ﹤0.01% 2400

Other funds holding CGON

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Point72 Asset Management's CGON Position: Q1 2026 in Review

Point72 Asset Management increased its CG Oncology (CGON) stake by 164% in Q1 2026, buying an estimated $14.1M and bringing the position to 399,392 shares worth $27M. The position accounts for 0.03% of the portfolio, ranked #660.

Point72 Asset Management first reported a position in CGON in Q1 2024 and has held it in 9 quarters since. The position peaked at $61.4M in Q3 2025. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • Point72 Asset Management held 399,392 shares of CG Oncology worth $27M as of Q1 2026.
  • Point72 Asset Management bought 248,029 CG Oncology shares in Q1 2026, an estimated $14.1M.
  • CG Oncology made up 0.03% of Point72 Asset Management's portfolio in Q1 2026, its #660 holding.
  • Point72 Asset Management first reported a position in CG Oncology in Q1 2024 and has held it in 9 quarters since.
  • Point72 Asset Management's CG Oncology position peaked at $61.4M in Q3 2025.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.